Recent

% | $
Quotes you view appear here for quick access.

Prana Biotechnology Limited Message Board

soundsgood02 119 posts  |  Last Activity: Mar 25, 2015 2:18 PM Member since: Jul 26, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • soundsgood02 soundsgood02 Mar 25, 2015 2:18 PM Flag

    They controlled the company even before the last financing...And they decided,not Spiro,to acquire 40% of Cycc at $1...imo...

  • soundsgood02 soundsgood02 Mar 25, 2015 1:11 PM Flag

    If he continue to stay there after all these negative years, evidently the owners (big shareholders and financiers) of this company are satisfied of his job...They know the obscure reasons ...

  • Reply to

    MX-ICP launch delayed

    by abraham_xin Mar 24, 2015 10:09 AM
    soundsgood02 soundsgood02 Mar 24, 2015 11:02 AM Flag

    To close this topic...Considering that we are in the last week of first quarter,the possibility of delay exist...A stock collapse from this level is unlilkely...

    Sentiment: Buy

  • Reply to

    MX-ICP launch delayed

    by abraham_xin Mar 24, 2015 10:09 AM
    soundsgood02 soundsgood02 Mar 24, 2015 10:56 AM Flag

    ..Share your source with me...Or you are trying to buy very cheap shares?

    Sentiment: Buy

  • Reply to

    MX-ICP launch delayed

    by abraham_xin Mar 24, 2015 10:09 AM
    soundsgood02 soundsgood02 Mar 24, 2015 10:38 AM Flag

    A very big information to be your first post ever...Newbie or new ID?

    abraham_xin 1 post | Last Activity: 24 minutes ago Member since: Mar 24, 2015

  • Reply to

    Standard of Care!

    by boderoniol5 Mar 24, 2015 8:41 AM
    soundsgood02 soundsgood02 Mar 24, 2015 8:55 AM Flag

    Liquid biopsy will be standard of care...The visibility of liquid biopsy producers still quite low...

    Sentiment: Buy

  • Reply to

    New Oncology Plans with Liquid Biopsy (BIOC)

    by chemeng4118 Mar 23, 2015 11:29 PM
    soundsgood02 soundsgood02 Mar 24, 2015 7:06 AM Flag

    NEW YORK (GenomeWeb) – German MDx firm New Onclogy is planning to launch a liquid biopsy cancer mutation test this year supported by an undisclosed amount raised in a funding round this week.

    An offshoot of German contract research and analytics firm Blackfield, New Oncology currently offers a targeted sequencing assay called NeoPlus, which profiles more than 70 cancer-associated genes for point mutations, gene amplifications, gene fusions, and other rearrangements using a target amplification and sequencing strategy.

  • Reply to

    TBIO another liquid biopsy play..

    by soundsgood02 Mar 11, 2015 2:30 PM
    soundsgood02 soundsgood02 Mar 23, 2015 12:38 PM Flag

    Expected News this week ...Green after quadruple bottom...

    Sentiment: Strong Buy

  • Reply to

    from HealthCanal (3/18/15): Part 2

    by b_f_l_o Mar 21, 2015 3:08 PM
    soundsgood02 soundsgood02 Mar 21, 2015 4:43 PM Flag

    Liquid biopsy has a great future ...It will be standard of care within 2-3 years...Strong buy for all the involved stocks ...

  • 2014;22(2):114-8. doi: 10.1097/PDM.0b013e31829a638d.
    The "COLD-PCR approach" for early and cost-effective detection of tyrosine kinase inhibitor resistance mutations in EGFR-positive non-small cell lung cancer.
    Mairinger FD1, Vollbrecht C, Streubel A, Roth A, Landt O, Walter HF, Kollmeier J, Mairinger T.
    Author information

    1*Institute of Pathology and Neuropathology, University Hospital Essen, University of Duisburg-Essen ∥Department of Interventional Pneumology, Ruhrlandklinik-University Hospital, Essen †Institute of Pathology, University Hospital Cologne, Cologne Departments of ‡Pathology ¶Pneumology, Helios Klinikum Emil von Behring §TIB MOLBIOL Syntheselabor GmbH, Berlin, Germany.

    Abstract
    BACKGROUND:

    Activating epidermal growth factor receptor (EGFR) gene mutations can be successfully treated by EGFR tyrosine kinase inhibitors (EGFR-TKIs), but nearly 50% of all patients' exhibit progression of the disease until treatment because of T790M mutations. It is proposed that this is mostly caused by therapy-resistant tumor clones harboring a T790M mutation. Until now no cost-effective routine-diagnostic method for EGFR-resistance mutation status analysis is available leaving long-time response to TKI treatment to chance. Unambiguous identification of T790M EGFR mutations is mandatory to optimize initial treatment strategies.
    MATERIALS AND METHODS:

    Artificial EGFR T790M mutations and human wild-type gDNA were prepared in several dilution series. Preferential amplification using coamplification at lower denaturation temperature-PCR (COLD-PCR) of the mutant sequence and subsequent HybProbe melting curve detection or pyrosequencing were performed in comparison to normal processing.
    RESULTS:

    COLD-PCR-based amplification allowed the detection of 0.125% T790M mutant DNA in a background of wild-type DNA in comparison to 5% while normal processing. These results were reproducible.
    CONCLUSIONS:

    COLD-PCR is a powerful and cost-effective tool for routine diagnostic to detect underrepresented tumor clones in clinical samples. A diagnostic tool for unambiguous identification of T790M-mutated minor tumor clones is now available enabling optimized therapy.

  • Reply to

    JAMA Article on Breast Biopsy Accuracy

    by b_f_l_o Mar 18, 2015 3:23 PM
    soundsgood02 soundsgood02 Mar 18, 2015 5:40 PM Flag

    Conclusions and Relevance In this study of pathologists, in which diagnostic interpretation was based on a single breast biopsy slide, overall agreement between the individual pathologists’ interpretations and the expert consensus–derived reference diagnoses was 75.3%, with the highest level of concordance for invasive carcinoma and lower levels of concordance for DCIS and atypia. Further research is needed to understand the relationship of these findings with patient management.

  • Reply to

    JAMA Article on Breast Biopsy Accuracy

    by b_f_l_o Mar 18, 2015 3:23 PM
    soundsgood02 soundsgood02 Mar 18, 2015 5:39 PM Flag

    and among benign cases without atypia (2070 interpretations), 87% (95% CI, 85%-89%) were concordant and 13% (95% CI, 11%-15%) were overinterpreted. Disagreement with the reference diagnosis was statistically significantly higher among biopsies from women with higher (n = 122) vs lower (n = 118) breast density on prior mammograms (overall concordance rate, 73% [95% CI, #$%$] for higher vs 77% [95% CI, 75%-80%] for lower, P 

  • Reply to

    JAMA Article on Breast Biopsy Accuracy

    by b_f_l_o Mar 18, 2015 3:23 PM
    soundsgood02 soundsgood02 Mar 18, 2015 5:39 PM Flag

    importance A breast pathology diagnosis provides the basis for clinical treatment and management decisions; however, its accuracy is inadequately understood.

    Objectives To quantify the magnitude of diagnostic disagreement among pathologists compared with a consensus panel reference diagnosis and to evaluate associated patient and pathologist characteristics.

    Design, Setting, and Participants Study of pathologists who interpret breast biopsies in clinical practices in 8 US states.

    Exposures Participants independently interpreted slides between November 2011 and May 2014 from test sets of 60 breast biopsies (240 total cases, 1 slide per case), including 23 cases of invasive breast cancer, 73 ductal carcinoma in situ (DCIS), 72 with atypical hyperplasia (atypia), and 72 benign cases without atypia. Participants were blinded to the interpretations of other study pathologists and consensus panel members. Among the 3 consensus panel members, unanimous agreement of their independent diagnoses was 75%, and concordance with the consensus-derived reference diagnoses was 90.3%.

    Main Outcomes and Measures The proportions of diagnoses overinterpreted and underinterpreted relative to the consensus-derived reference diagnoses were assessed.

    Results Sixty-five percent of invited, responding pathologists were eligible and consented to participate. Of these, 91% (N = 115) completed the study, providing 6900 individual case diagnoses. Compared with the consensus-derived reference diagnosis, the overall concordance rate of diagnostic interpretations of participating pathologists was 75.3% (95% CI, 73.4%-77.0%; 5194 of 6900 interpretations). Among invasive carcinoma cases (663 interpretations), 96% (95% CI, 94%-97%) were concordant, and 4% (95% CI, 3%-6%) were underinterpreted; among DCIS cases (2097 interpretations), 84% (95% CI, 82%-86%) were concordant, 3% (95% CI, 2%-4%) were overinterpreted, and 13% (95% CI, 12%-15%) were underinterpreted;

  • soundsgood02 soundsgood02 Mar 18, 2015 1:34 PM Flag

    ...Liquid biopsy stocks= screaming buy...BIOC TBIO

  • Reply to

    TBIO another liquid biopsy play..

    by soundsgood02 Mar 11, 2015 2:30 PM
    soundsgood02 soundsgood02 Mar 18, 2015 1:09 PM Flag

    Screaming buy...Like Bioc at $1,1...

  • soundsgood02 soundsgood02 Mar 17, 2015 7:07 PM Flag

    Good news for the patient ...But not big for imrs...Princess Margaret Centre is an old Imris customer with the MRI purchased some years ago..No revenue from this centre..Positive for future deals...

    Sentiment: Hold

  • Reply to

    TBIO another liquid biopsy play..

    by soundsgood02 Mar 11, 2015 2:30 PM
    soundsgood02 soundsgood02 Mar 17, 2015 8:36 AM Flag

    2014;22(2):114-8. doi: 10.1097/PDM.0b013e31829a638d.
    The "COLD-PCR approach" for early and cost-effective detection of tyrosine kinase inhibitor resistance mutations in EGFR-positive non-small cell lung cancer.
    Mairinger FD1, Vollbrecht C, Streubel A, Roth A, Landt O, Walter HF, Kollmeier J, Mairinger T.
    Author information

    1*Institute of Pathology and Neuropathology, University Hospital Essen, University of Duisburg-Essen ∥Department of Interventional Pneumology, Ruhrlandklinik-University Hospital, Essen †Institute of Pathology, University Hospital Cologne, Cologne Departments of ‡Pathology ¶Pneumology, Helios Klinikum Emil von Behring §TIB MOLBIOL Syntheselabor GmbH, Berlin, Germany.

    Abstract
    BACKGROUND:

    Activating epidermal growth factor receptor (EGFR) gene mutations can be successfully treated by EGFR tyrosine kinase inhibitors (EGFR-TKIs), but nearly 50% of all patients' exhibit progression of the disease until treatment because of T790M mutations. It is proposed that this is mostly caused by therapy-resistant tumor clones harboring a T790M mutation. Until now no cost-effective routine-diagnostic method for EGFR-resistance mutation status analysis is available leaving long-time response to TKI treatment to chance. Unambiguous identification of T790M EGFR mutations is mandatory to optimize initial treatment strategies.
    MATERIALS AND METHODS:

    Artificial EGFR T790M mutations and human wild-type gDNA were prepared in several dilution series. Preferential amplification using coamplification at lower denaturation temperature-PCR (COLD-PCR) of the mutant sequence and subsequent HybProbe melting curve detection or pyrosequencing were performed in comparison to normal processing.
    RESULTS:

    COLD-PCR-based amplification allowed the detection of 0.125% T790M mutant DNA in a background of wild-type DNA in comparison to 5% while normal processing. These results were reproducible.
    CONCLUSIONS:

    COLD-PCR is a powerful and cost-effective tool for routine diagnostic to detect underrepresented tumor clones in clinical samples. A diagnostic tool for unambiguous identification of T790M-mutated minor tumor clones is now available enabling optimized therapy.

  • Reply to

    TBIO another liquid biopsy play..

    by soundsgood02 Mar 11, 2015 2:30 PM
    soundsgood02 soundsgood02 Mar 16, 2015 1:56 PM Flag

    Ultrasensitive detection and identification of BRAF V600 mutations in fresh frozen, FFPE, and plasma samples of melanoma patients by E-ice-COLD-PCR.

    2014 Sep;406(22):5513-20. doi: 10.1007/s00216-014-7975-5. Epub 2014 Jun 27.
    Ultrasensitive detection and identification of BRAF V600 mutations in fresh frozen, FFPE, and plasma samples of melanoma patients by E-ice-COLD-PCR.
    How-Kit A1, Lebbé C, Bousard A, Daunay A, Mazaleyrat N, Daviaud C, Mourah S, Tost J.
    Author information

    1Laboratory for Functional Genomics, Fondation Jean Dausset - CEPH, 75010, Paris, France.

    Abstract

    A number of molecular diagnostic methods have been developed for the detection and identification of mutations in tumor samples, which are important for the choice of treatment in the context of personalized medicine. For the treatment of metastatic melanoma, Vemurafenib is recommended for patients with BRAF V600 activating mutations. However, the different assays developed to date for the detection of these mutations lack sensitivity or specificity or do not allow a sequencing-based identification or validation of the mutation. Recently, enhanced improved and complete enrichment co-amplification at lower denaturation temperature-polymerase chain reaction (E-ice-COLD-PCR) has been developed as a sensitive method for the detection and identification of mutations in KRAS codons 12/13. Here, we present the first E-ice-COLD-PCR assay for the detection and identification of BRAF codon 600 mutations, which has a large dynamic range, as 25 pg to 25 ng can be used as DNA input without any reduction in mutation enrichment efficiency, and which can detect down to 0.01 % of mutated alleles in a wild-type background. The assay has been validated on fresh frozen, formalin-fixed paraffin-embedded (FFPE), and plasma samples of melanoma patients and has allowed the detection and identification of BRAF mutations present in samples appearing as wild type using standard pyrosequencing, endpoint genotyping, or Sanger sequencing. Thus, the BRAF V600 E-ice-COLD-PCR assay is currently one of the most powerful molecular diagnostic tools for the ultrasensitive detection and identification of BRAF codon 600 mutations

  • soundsgood02 by soundsgood02 Mar 16, 2015 11:11 AM Flag

    The company will need at least another financing to arrive at significant Symbis revenue..Not before of beginning or mid 2016(according to CEO CC)...Maybe they are preparing another round for them at discount price...

    Sentiment: Hold

  • 2014 Sep;406(22):5513-20. doi: 10.1007/s00216-014-7975-5. Epub 2014 Jun 27.
    Ultrasensitive detection and identification of BRAF V600 mutations in fresh frozen, FFPE, and plasma samples of melanoma patients by E-ice-COLD-PCR.
    How-Kit A1, Lebbé C, Bousard A, Daunay A, Mazaleyrat N, Daviaud C, Mourah S, Tost J.
    Author information

    1Laboratory for Functional Genomics, Fondation Jean Dausset - CEPH, 75010, Paris, France.

    Abstract

    A number of molecular diagnostic methods have been developed for the detection and identification of mutations in tumor samples, which are important for the choice of treatment in the context of personalized medicine. For the treatment of metastatic melanoma, Vemurafenib is recommended for patients with BRAF V600 activating mutations. However, the different assays developed to date for the detection of these mutations lack sensitivity or specificity or do not allow a sequencing-based identification or validation of the mutation. Recently, enhanced improved and complete enrichment co-amplification at lower denaturation temperature-polymerase chain reaction (E-ice-COLD-PCR) has been developed as a sensitive method for the detection and identification of mutations in KRAS codons 12/13. Here, we present the first E-ice-COLD-PCR assay for the detection and identification of BRAF codon 600 mutations, which has a large dynamic range, as 25 pg to 25 ng can be used as DNA input without any reduction in mutation enrichment efficiency, and which can detect down to 0.01 % of mutated alleles in a wild-type background. The assay has been validated on fresh frozen, formalin-fixed paraffin-embedded (FFPE), and plasma samples of melanoma patients and has allowed the detection and identification of BRAF mutations present in samples appearing as wild type using standard pyrosequencing, endpoint genotyping, or Sanger sequencing. Thus, the BRAF V600 E-ice-COLD-PCR assay is currently one of the most powerful molecular diagnostic tools for the ultrasensitive detection and identification of BRAF codon 600 mutations.

PRAN
1.15+0.0300(+2.68%)Mar 27 3:58 PMEDT